Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366871 · ClinicalTrials.gov registry record · Phase 2
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
A Phase 2 study of Gynecologic Cancer and Venous Thromboembolism, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 2
- Study locations
NCT02366871 is a Phase 2 study of Gynecologic Cancer and Venous Thromboembolism that has completed, run by University of Colorado, Denver. The registered enrollment target is 400 participants, below the 757-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02366871, a Phase 2 study of Gynecologic Cancer and Venous Thromboembolism, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous enoxaparin 40 mg once a day (QD) for 28 days post surgery.
Conditions Studied
Interventions
- DRUG Oral apixaban
- DRUG Subcutaneous enoxaparin
Study Locations (2)
California
- University of Southern California Keck School of Medicine - Los Angeles
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2019-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366871
The ClinicalTrials.gov registry entry for NCT02366871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 757-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (47% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Oral apixaban is the first listed.
NCT02366871 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02366871 about?
NCT02366871 is a clinical study titled "Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy". The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous enoxaparin 40 mg once a day (QD) for 2...
What is the current status of trial NCT02366871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2015-04-28. Estimated completion is 2019-06.
What conditions does trial NCT02366871 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Venous Thromboembolism.
What interventions are being tested in trial NCT02366871?
The interventions under investigation include: Oral apixaban (DRUG), Subcutaneous enoxaparin (DRUG).
Who is sponsoring clinical trial NCT02366871?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366871 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
RECRUITING · Phase 2
-
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.